



## Tumor Vaccines: Current Processes, Prevailing Challenges and Future Perspectives

Guest Editors:

**Dr. Xingxing He**

Department of Gastroenterology,  
Zhongnan Hospital of Wuhan  
University, Wuhan, China

**Prof. Dr. Honglin Jin**

College of Biomedicine and  
Health, Huazhong Agricultural  
University, Wuhan, China

Deadline for manuscript  
submissions:

**1 May 2025**

### Message from the Guest Editors

Dear Colleagues,

In recent years, immunotherapy has gained significant momentum in the field of cancer treatment. Tumor vaccines are a favorable approach to cancer immunotherapy and include mRNA vaccines, DNA vaccines, and others. Eventually, vaccination may become the first truly personalized treatment for cancer. mRNA vaccines have become a promising platform for cancer immunotherapy as SARS-CoV-2 vaccines based on mRNA platforms have been rigorously evaluated and approved for widespread use. To conclude, there are a variety of problems to address in the area of tumor vaccines.

This Special Issue aims to discuss the latest processes, prevailing challenges, and future perspectives related to the development of tumor vaccines. In this Special Issue, original research articles, case reports, and reviews are welcome. Research areas may include (but are not limited to) the following: basic research and clinical trials on tumor vaccines, the nature of tumor vaccines, vaccine adjuvants, and delivery strategies.

We look forward to receiving your contributions.

Dr. Xingxing He  
Prof. Dr. Honglin Jin  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)